Superworth

Anaptysbio EV/EBIT ANAB

Enterprise value divided by operating profit over the last twelve months, one-off items taken out, since 2021.

Today, Oct 23, 2026
n/m
a quarter missing
5-year median
41.6×
5-year range
32.8× to 86.7×
Peer median
9.4×

Anaptysbio's EV/EBIT can't be checked today: its operating income for Q4 FY26, the quarter to Jun 30, 2026, is missing from our data, so the twelve months it rests on can't be added up.

On the days it had one over the last 5 years, its median was 41.6×, from 32.8× in Mar 2026 to 86.7× in Nov 2021.

EV/EBIT over time

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far35.5×32.8×52.6×
2025n/m a value too high to mean anything
2024n/m a value too high to mean anything
2023n/m a value too high to mean anything
202262.3×61.4×74.8×
202178.4×61.4×86.7×

Against its peers

Companies in Drug Manufacturers - General nearest Anaptysbio's size, closest first, today.

CompanyEV/EBIT
ANABAnaptysbion/m
PCRXPacira BioSciences7.6×
PAHCPhibro Animal Health11.7×
ANIPANI Pharmaceuticals10.5×
OMEROmerosn/m
AMPHAmphastar Pharmaceuticals12.2×
HRMYHarmony Biosciences6.9×
PBHPrestige Consumer Healthcare14.5×
ABUSArbutus Biopharma4.9×
NRIXNurix Therapeutics7.1×
COLLCollegium Pharmaceutical9.4×
Peer median9.4×

What the EV/EBIT tells you

What the whole business costs against its operating profit. Enterprise value is the market value plus borrowings and minority interests, less cash. EBIT is operating profit before interest and tax, with one-offs taken out. Unlike PE it is not moved by how a company is financed.

Leases are left out of debt for every company. Banks earn on their balance sheet, so EV/EBIT does not describe them.

More on Anaptysbio

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.